2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow EBV: new trials by email Literature Review of EBV trials Research Report on EBV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults VXCO-102, Placebo - EBV | Phase 1 | Recruiting | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 82 | 2026-11-16 | 2026-10-26 |
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection EBV gp350-ferritin vaccine with ALFQ adjuvant, EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant - EBV, Epstein-Barr Virus Infection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 750 | 2025-05-29 | 2026-10-26 |
Epstein-Barr Virus Infections (2) · Infectious Mononucleosis (1)
DNA Virus Infections (2) · Herpesviridae Infections (2) · Infections (2) · Tumor Virus Infections (2) · Virus Diseases (2) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukocyte Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
National Institute of Allergy and Infectious Diseases (NIAID) (1) · Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (1)
Australia (1) · United States (1)